Trial Profile
An Open-Label Multicenter Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SBC-102 in Adult Participants With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Sebelipase alfa (Primary)
- Indications Wolman disease
- Focus Adverse reactions
- Sponsors Alexion AstraZeneca Rare Disease; Synageva BioPharma
- 24 Nov 2014 New trial record